Skip to main content

Advertisement

Table 1 Main patient and tumour characteristics (n = 258)

From: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Characteristics
Median age at diagnosis; years (range) 50 (18–80)
Histological type of primary tumour; n (%)
 Ductal 228 (88.4)
 Lobular 21 (8.1)
 Other subtypes 9 (3.5)
Tumour subgroup; n (%)
 ER-positive 184 (71.32)
 PR-positive 122 (47.29)
 HR-positive 189 (73.3)
 HER2-positive 26 (10.2)
 Triple negative 58 (22.5)
ECOG performance status (%)
 0 73 (28.3)
 1 133 (51.6)
 2 46 (17.8)
 3 6 (2.3)
Previous chemotherapy for (neo) adjuvant/advanced disease
 Anthracyclines; n (%) 244 (94.6)
 Taxanes; n (%) 253 (98.1)
 Capecitabine; n (%) 234 (90.7)
 Median prior lines of chemotherapy in the metastatic setting (range) 4 (1–9)
Best response under previous taxane therapy; n (%)
 Complete response 20 (7.8)
 Partial response 112 (43.8)
 Stable disease 78 (30.5)
 Progressive disease 33 (12.9)
 Not evaluable 13 (5.1)
 Missing 2
Hormonal therapy
 Prior hormonal therapy (HR+ tumours; n [%]) 184 (97.3)
Metastatic sites; n (%)
 Visceral metastases 223 (86.4)
  Liver 174 (67.4)
  Node 118 (45.7)
  Lung 98 (38.0)
  Brain 41 (15.9)
  Serous 55 (21.3)
  Skin 31 (12.0)
 Bone 176 (68.2)
 Other sites 26 (10.1)